Friday, October 14, 2011. I love the how the PR people put spins on data. Health care giant Johnson and Johnson likely will discuss its pipeline, recent drug approvals and several important deals when it reports its third-quarter results before the stock market opens Tuesday. The company may OR NOT! Give updates on several pending deals.

Quinta-feira, 19 de maio de 2011.

Thursday, December 13, 2007. The development of mechanical and bio-synthetic devices has sprung new hope for those with impaired vision. However, current artificial vision technology can only aid those who have lost their vision later in life and still have a fairly intact visual system. Unfortunately, to date, no visual prosthesis has been able to restore vision to people who are born blind due to structural defects in the eye or visual cortex. Over the past three decades, various technologies have been.

The joint BioTech 2008 and the 4. The further potential of recombinant yeasts, in particular Pichia pastoris, Hansenula polymorpha, Yarrowia lipolytica,. Molecular biology tools for pathway engineering and custom-designed glycosylation.

Tuesday, November 11, 2008. This is a wonderful opportunity to connect innovation in the region with the commercialization infrastructure. The 3rd group of posters is currently being presented so you still have the chance to speak with the investigators. Thanks to everyone on the Innovation Corridor planning committee , my co-chair Chris Yochim from AstraZeneca and the great support from BIONJ and Pennsylvania BIO for making Innovation Corrridor a success. New Jersey Institute of Technology.